Wedbush Upgrades Zentalis Pharmaceuticals to Outperform, Raises Price Target to $6
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsUpgradesPrice Target
Wedbush analyst Robert Driscoll upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) from Neutral to Outperform and raises the price target from $5 to $6.
Wedbush analyst Robert Driscoll upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) from Neutral to Outperform and raises the price target from $5 to $6.